Pharmaceutical Executive
CMS Signals Looming Sunshine Act Audits: How to Prepare
March 1, 2024
New guidance suggests that CMS may be ramping up Sunshine Act auditing activities, potentially resulting in monetary liability for noncompliant reporting entities.
After more than a decade of relative inactivity, the Centers for Medicare & Medicaid Services(CMS) has signaled that it may soon commence audits of reporting entities under the Sunshine Act.
Published by Pharmaceutical Executive on March 1, 2024, available at https://www.pharmexec.com/view/cms-signals-looming-sunshine-act-audits-how-to-prepare.
Contacts
Capabilities
Suggested News & Insights
BIOSECURE Act Included in the FY2026 National Defense Authorization ActDecember 12, 2025U.S. Drug Pricing Year in Review: Reflections on 2025 and Getting Ready for 2026December 11, 2025What the U.S.–UK Drug Pricing Agreement Reveals About How MFN Drug Policy Could Impact the UK and EUDecember 10, 2025Sidley Represents Lumexa Imaging in US$462.5 Million Initial Public OfferingDecember 10, 2025First Circuit Clarifies Application of Medicare’s “Reasonable and Necessary” Standard in FCA Cases Against Clinical LabsDecember 8, 2025Medicare Payment Policy Final Rule for Outpatient Setting Addresses Radiopharmaceuticals, Skin Substitutes, and 340B Program Key TopicsDecember 2, 2025
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory


